Azathioprine in the treatment of thyroid-associated ophthalmopathy.
Azathioprine is used in the treatment of thyroid-associated ophthalmopathy, but its effectiveness has not been evaluated. In the present study 20 patients with moderately severe ophthalmopathy were recruited; 10 patients received azathioprine and the other 10 matched patients served as controls. During the treatment period (lasting 1 year) and 1 year later, no changes were detected in exophthalmometer readings, visual acuity or measurement of palpebral aperture. Differential intraocular pressure fell with time in both groups. Azathioprine treatment did not significantly influence these parameters, although it did induce significant decrease in thyroid microsomal antibodies and in thyroid-stimulating hormone binding inhibiting immunoglobulin index. The study demonstrates that thyroid-associated ophthalmopathy of moderate severity, often improves with time without treatment. Azathioprine is not an effective treatment for patients with moderately severe thyroid-associated ophthalmopathy. The study emphasises the necessity for an adequately matched control population in the evaluation of therapy.
Perros
P
P
Department of Medicine, Medical School, University of Newcastle upon Tyne, UK.
Weightman
D R
DR
Crombie
A L
AL
Kendall-Taylor
P
P
D001379:Azathioprine / Q000627:therapeutic use*; D004341:Drug Evaluation; D005094:Exophthalmos / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006111:Graves Disease / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D007429:Intraocular Pressure; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies
D001379:Azathioprine